| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 |
| filingDate |
2020-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39c1d23114f10a958dc0fc8547b9b571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_914b5739a5831a4fa38ffad5f91c9b62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d193ca5c870359e0ccf76f15d483fdbd |
| publicationDate |
2022-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-114729370-A |
| titleOfInvention |
Cross-species anti-latent TGF-β1 antibodies and methods of use |
| abstract |
It is an object of the present invention to provide cross-species anti-latent TGF-β1 antibodies that inhibit protease-mediated activation of latent TGF-β1 without inhibiting integrin-mediated activation of latent TGF-β1. In order to obtain the anti-latent TGF-β1 antibody of the present invention, an anti-latent TGF-β1 antibody that inhibits protease-mediated activation of latent TGF-β1 without inhibiting integrin-mediated activation of latent TGF-β1 was screened, and then performed Humanization, and further optimization. The present invention also provides a combination therapy comprising an anti-latent TGF-β1 antibody and one or more immune checkpoint inhibitors, preferably a PD-1 axis binding antagonist. |
| priorityDate |
2019-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |